Overview

Aspirin Resistance and Percutaneous Coronary Intervention (PCI)

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention (PCI).
Phase:
Phase 2
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Treatments:
Abciximab
Aspirin
Cangrelor
Clopidogrel
Eptifibatide
Krestin
polysaccharide-K
Prasugrel Hydrochloride
Ticlopidine
Tirofiban